Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
Patient Out-of-Pocket Costs for Guideline-Recommended Treatments for Erectile Dysfunction: A Medicare Cost Modeling Analysis - Beyond the Abstract ...
Robotic versus Open Cystectomy with Ileal Conduit for the Management of Neurogenic Bladder: A Comparative Study - Beyond the Abstract ...
Varicocele and Sperm DNA Fragmentation: New Evidence with Implications for Clinical Practice - Beyond the Abstract ...
Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...
Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases. December 2, 2025 Assessing risk ...
(UroToday.com) The 2025 SUO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Reuben Ben-David discussing preoperative ctDNA predicting upstaging and recurrence in ...
Prostate cancer, while commonly diagnosed in early forms, remains the second leading cause of cancer mortality in the United States and Europe. 1 For patients who die of prostate cancer, some will be ...
Read the Full Video Transcript Zach Klaassen: Hi, my name is Dr. Zach Klaassen, and I'm a urologic oncologist at the Georgia Cancer Center in Augusta, Georgia. And we're here in San Francisco at ...
Zachary Klaassen is joined by Neil Mariados, the lead author on both the SpaceOAR™ and Barrigel® trials to discuss rectal spacing, which is used in radiation therapy to reduce rectal toxicity in ...
Combination Lenvatinib-Tislelizumab for Fumarate Hydratase-Deficient Renal Cell Carcinoma - Wen Kong
Read the Full Video Transcript Pedro Barata: Hello, everyone. I'm Pedro Barata. I'm a GU oncologist at Case Western Reserve University in Cleveland, Ohio. I'm happy to be here today, joined by Dr. Wen ...
Karim Fizazi discusses updated overall survival data from the TALAPRO-2 trial. Dr. Fizazi focuses on the HRR mutation cohort comparing talazoparib plus enzalutamide versus enzalutamide alone in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback